These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 31503216)

  • 61. Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients.
    Chanchlani N; Lin S; Chee D; Hamilton B; Nice R; Arkir Z; Bewshea C; Cipriano B; Derikx LAAP; Dunlop A; Greathead L; Griffiths RL; Ibraheim H; Kelleher P; Kok KB; Lees CW; MacDonald J; Sebastian S; Smith PJ; McDonald TJ; Irving PM; Powell N; Kennedy NA; Goodhand JR; Ahmad T
    J Crohns Colitis; 2022 Mar; 16(3):389-397. PubMed ID: 34473254
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Antibiotic use differentially affects the risk of anti-drug antibody formation during anti-TNFα therapy in inflammatory bowel disease patients: a report from the epi-IIRN.
    Gorelik Y; Freilich S; Gerassy-Vainberg S; Pressman S; Friss C; Blatt A; Focht G; Weisband YL; Greenfeld S; Kariv R; Lederman N; Dotan I; Geva-Zatorsky N; Shen-Orr SS; Kashi Y; Chowers Y;
    Gut; 2022 Feb; 71(2):287-295. PubMed ID: 34344783
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease.
    Mitrev N; Leong RW
    Expert Opin Drug Saf; 2017 Mar; 16(3):303-317. PubMed ID: 27922765
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Therapeutic drug monitoring was helpful in guiding the decision-making process for children receiving infliximab for inflammatory bowel disease.
    Deora V; Kozak J; El-Kalla M; Huynh HQ; El-Matary W
    Acta Paediatr; 2017 Nov; 106(11):1863-1867. PubMed ID: 28779489
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease.
    Aardoom MA; Veereman G; de Ridder L
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126015
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
    Chaparro M; Barreiro-de Acosta M; Echarri A; Almendros R; Barrio J; Llao J; Gomollón F; Vera M; Cabriada JL; Guardiola J; Guerra I; Beltrán B; Roncero O; Busquets D; Taxonera C; Calvet X; Ferreiro-Iglesias R; Ollero Pena V; Bernardo D; Donday MG; Garre A; Godino A; Díaz A; Gisbert JP
    Dig Dis Sci; 2019 Mar; 64(3):846-854. PubMed ID: 30426297
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Infections in inflammatory bowel disease patients on immunomodulator and biologic therapy are not associated with high serum drug levels.
    Gazelakis K; Chu I; Martin C; Sparrow MP
    Intern Med J; 2024 Jan; 54(1):139-148. PubMed ID: 37151186
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Patterns of anti-TNF use and associated treatment outcomes in inflammatory bowel disease patients: results from an analysis of Dutch health insurance claims data.
    Bots SJA; Hoekman DR; Benninga MA; Ponsioen CY; D'Haens GR; Löwenberg M
    Neth J Med; 2017 Dec; 75(10):432-442. PubMed ID: 29256410
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug?
    Papamichael K; Cheifetz AS
    Curr Opin Gastroenterol; 2019 Jul; 35(4):302-310. PubMed ID: 30973355
    [TBL] [Abstract][Full Text] [Related]  

  • 70. IMPORTANCE OF MEASURING LEVELS OF INFLIXIMAB IN PATIENTS TREATING INFLAMMATORY BOWEL DISEASE IN A BRAZILIAN COHORT.
    Kampa KC; Morsoletto DBG; Loures MR; Pissaia A; Nones RB; Ivantes CAP
    Arq Gastroenterol; 2017 Dec; 54(4):333-337. PubMed ID: 28954041
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Gene Signatures of Early Response to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease.
    Salvador-Martín S; Raposo-Gutiérrez I; Navas-López VM; Gallego-Fernández C; Moreno-Álvarez A; Solar-Boga A; Muñoz-Codoceo R; Magallares L; Martínez-Ojinaga E; Fobelo MJ; Millán-Jiménez A; Rodriguez-Martinez A; Vayo CA; Sánchez C; Tolin M; Bossacoma F; Pujol-Muncunill G; González de Caldas R; Loverdos I; Blanca-García JA; Segarra O; Eizaguirre FJ; García-Romero R; Merino-Bohórquez V; Sanjurjo-Sáez M; López-Fernández LA
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397546
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
    Carman N; Mack DR; Benchimol EI
    Curr Gastroenterol Rep; 2018 Apr; 20(5):18. PubMed ID: 29623442
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Do Not Stop Anti-TNF Medications in Children With IBD When They Are Working.
    Adler J; Lee GJ; Singer AAM
    Inflamm Bowel Dis; 2022 Feb; 28(2):322-324. PubMed ID: 33835170
    [No Abstract]   [Full Text] [Related]  

  • 75. Therapeutic Drug Monitoring for Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease.
    Dutt K; Vasudevan A
    Medicina (Kaunas); 2024 Jan; 60(2):. PubMed ID: 38399538
    [No Abstract]   [Full Text] [Related]  

  • 76. A Systematic Review on the Interest of Drug-tolerant Assay in the Monitoring of Inflammatory Bowel Disease.
    Barrau M; Duprat M; Veyrard P; Tournier Q; Williet N; Marc Phelip J; Waeckel L; Cheifetz AS; Papamichael K; Roblin X; Paul S
    J Crohns Colitis; 2023 Apr; 17(4):633-643. PubMed ID: 36301958
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A Genetic Variation in the Neonatal Fc-Receptor Affects Anti-TNF Drug Concentrations in Inflammatory Bowel Disease.
    Billiet T; Dreesen E; Cleynen I; Wollants WJ; Ferrante M; Van Assche G; Gils A; Vermeire S
    Am J Gastroenterol; 2016 Oct; 111(10):1438-1445. PubMed ID: 27481307
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents.
    Eickstaedt JB; Killpack L; Tung J; Davis D; Hand JL; Tollefson MM
    Pediatr Dermatol; 2017 May; 34(3):253-260. PubMed ID: 28211161
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis: A nationwide case series.
    Altwegg R; Combes R; Laharie D; De Ledinghen V; Radenne S; Conti F; Chazouilleres O; Duvoux C; Dumortier J; Leroy V; Treton X; Durand F; Dharancy S; Nachury M; Goutorbe F; Lamblin G; Boivineau L; Peyrin-Biroulet L; Pageaux GP
    Dig Liver Dis; 2018 Jul; 50(7):668-674. PubMed ID: 29655972
    [TBL] [Abstract][Full Text] [Related]  

  • 80. New Onset Autoimmune Hepatitis during Anti-Tumor Necrosis Factor-Alpha Treatment in Children.
    Ricciuto A; Kamath BM; Walters TD; Frost K; Carman N; Church PC; Ling SC; Griffiths AM
    J Pediatr; 2018 Mar; 194():128-135.e1. PubMed ID: 29274889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.